Insights from the DEVOTE Trial with Insulin Degludec
The DEVOTE study demonstrated that insulin degludec is associated with less severe daytime hypoglycemia and nocturnal hypoglycemia when used in patients with type 2 diabetes at high risk of cardiovascular events. The findings of this study can have important implications for the selection of insulin treatment in patients with type 2 diabetes.
Vincent Woo, MD, FRCPC
Gihane Zarifa, MD